drugset
drugset / Trial / NCT07548060

A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy

NCT07548060 ↗

Phase 2 Recruiting 25 enrolled Tianjin Medical University Cancer Institute and Hospital
NaSingle-groupOpen-labelTreatment

Summary

Efficacy and Safety of Sacituzumab Tirumotecan Combined with Furmonertinib in Patients with Locally Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy.

Timeline

Start
2026-02-01
Primary completion
2028-01-22
Completion
2028-01-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Firmonertinib Small molecule 80 mg —
Subject Sacituzumab Tirumotecan Other / unclassified 5 mg/kg Intravenous

Indications

non-small cell lung carcinoma